COVID-19 Plan: Checklists for Chronic Lymphocytic Leukemia (CLL) Preparing for Pre and Post COVID-19 Exposure
This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Expert Perspectives on Incorporating BTK Inhibitors into the Treatment Plan for Patients with CLL: Helpful Information for Patients and their Caregivers
Archived Webinar from September 3
Through a collaboration between CLL Society, Plexus Communications, and the Association of VA Hematology/Oncology (AVAHO), we invite you to view the archived webinar with Parameswaran Venugopal, MD from Rush University Medical Center in Chicago, IL, moderated by Bruce Wright, a Patient Advisor and Patient Educator for the CLL Society. Bruce is a United States military veteran who speaks to some of the challenges that are specific to veterans seeking treatment, as well as how patients and caregivers can increase their knowledge about CLL and become more involved in their treatment decisions. This webinar provides CLL patients and caregivers with information on the clinical use of BTK inhibitors for the treatment of their CLL to equip patients with the appropriate knowledge to make informed decisions with their care providers.
Related posts
